Why Dupixent Is a Mass Tort Opportunity Right Now

Why the Dupixent Lawsuit Side Effects 2026 Wave is Starting Now

Dupixent (dupilumab) mass tort litigation is an active case development opportunity in 2026 involving alleged severe adverse effects including ocular surface disease and paradoxical eosinophilia, with no MDL consolidation yet established. The biologic, co-marketed by Sanofi and Regeneron, generates Dupixent (dupilumab) is one of the best-selling drugs in the world. Sanofi and Regeneron move $14 billion annually on this IL-4/IL-13 blocker, which treats atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis. But post-market surveillance has uncovered a dark side: severe ocular surface disease, paradoxical eosinophilia, and in some patients, worsening of the very condition the drug was meant to treat. The Dupixent lawsuit side effects 2026 litigation wave is emerging now because the evidence is mounting, FAERS data is substantial, and plaintiff attorneys are starting to move. This is your window to build a case portfolio before consolidation.4 billion annually for treating atopic dermatitis, asthma, and related conditions. Mounting FAERS reports, expanding post-market surveillance data, and early plaintiff filings indicate this window presents optimal case acquisition timing before potential MDL centralization.

We’ve managed $250 million in ad spend across 600+ plaintiff law firms and 100+ mass torts. We’ve seen emerging torts move from zero claimants to five-figure case loads in 18 months. Dupixent is that opportunity right now. The drug has massive exposure, the side effects are documented in peer-reviewed journals, FDA labels have been updated multiple times, and the defendants—Sanofi and Regeneron—knew about these risks earlier than they disclosed them. That’s the failure-to-warn theory that wins cases.

Legal Landscape: Emerging MDL, Failure-to-Warn Foundation

Dupixent litigation is in the pre-MDL stage. No federal MDL has been consolidated yet, which means cases are being filed in state courts and some federal districts. This is the sweet spot for early-moving plaintiff firms. You have discovery advantages, venue flexibility, and first-mover leverage in settlement conversations.

The causation story is strong. Dupixent blocks IL-4 and IL-13 signaling, which disrupts goblet cell function in the conjunctiva and other mucosal surfaces. This causes severe ocular surface disease: conjunctivitis, keratitis, limbal stem cell deficiency, and corneal damage in reported cases. Patients have documented vision loss and required corneal transplants or intensive ophthalmology intervention. Second, blocking these pathways can paradoxically redirect eosinophils to tissues, worsening inflammatory conditions—including the eosinophilic esophagitis that the drug was prescribed to treat. Published case series in peer-reviewed journals support both mechanisms.

FDA label updates have acknowledged these events multiple times. Conjunctivitis warnings, keratitis warnings, and eosinophilic event advisories now appear in prescribing information. These updates are knowledge-based failure-to-warn evidence. The defendants knew about these risks earlier, did not warn adequately earlier, and continued to market the drug without proportional risk disclosure. That’s negligence and breach of warranty.

Filing trends are emerging. Plaintiff attorneys are evaluating FAERS data, consulting with ophthalmologists and gastroenterologists, and building early case inventories. The first wave of state court filings is underway. This is when advertising spend generates the highest return: early in case development, before the MDL stabilizes, when CPL (cost per lead) is lowest and case quality is highest because you’re capturing patients earliest in their awareness cycle.

Who Qualifies: Injury Types, Statute of Limitations, and the Dupixent Lawsuit Side Effects 2026 Case Definition

Claimant eligibility for the Dupixent lawsuit side effects 2026 emerging mass tort centers on documented injury following Dupixent use. Here’s the specificity:

• Ocular surface disease: Conjunctivitis, keratitis, corneal abrasion, limbal stem cell deficiency, or documented corneal damage requiring ophthalmology treatment (drops, ointments, or surgical intervention) while on or shortly after discontinuing Dupixent.
• Paradoxical eosinophilia: Elevated eosinophil counts (absolute eosinophil count >1,500/μL or tissue eosinophilia) documented during Dupixent therapy, or worsening of eosinophilic esophagitis despite treatment with the drug.
• Ocular + systemic injury: Some patients report both eye disease and eosinophilic flares simultaneously, suggesting a unified mechanism of immune dysregulation.

Statute of limitations varies by state but generally runs 2–3 years from discovery of injury or from when a reasonable person should have discovered the connection between Dupixent and the adverse event. Some states allow longer tolling for latent injuries. This means patients prescribed Dupixent from 2015 onward (when the drug launched) may still fall within the window, depending on when they developed symptoms and when they connected those symptoms to the drug. The injury discovery window is broad, which means claimant pool is large.

Medical record requirements are straightforward: ophthalmology records documenting eye disease while on Dupixent, or gastroenterology/allergy records documenting eosinophil elevation or worsening EoE during treatment. These records are routinely available and often held by the prescribing dermatology or primary care practice that started the patient on Dupixent.

Co-morbidities don’t necessarily disqualify claimants. A patient with pre-existing mild atopic dermatitis who developed severe keratitis while on Dupixent still has a strong case. The injury is causally attributable to the drug if the eye disease was not present before treatment and developed or worsened during treatment.

The Advertising Opportunity: Claimant Pool Size and CPL Strategy

Dupixent has been prescribed to millions of patients since FDA approval in 2016. Dermatology alone: atopic dermatitis affects roughly 10–15 million Americans; Dupixent has captured significant market share. Add asthma (25+ million Americans), eosinophilic esophagitis (tens of thousands, but growing as diagnosis becomes more common), and nasal polyposis. The exposed population is in the millions.

Reported adverse event rates in FAERS data show ocular side effects in a subset—not all patients, but enough to suggest systematic causation. Conjunctivitis is reported in 5–15% of some cohorts in case series. Even at conservative 2–3% serious ocular event rates across the exposed population, that’s 40,000 to 100,000+ claimants nationwide. Add paradoxical eosinophilia cases, and the pool expands further.

We’ve seen CPL (cost per lead) in emerging torts like this run $40–$120 per qualified lead on Facebook, depending on targeting specificity and geographic saturation. For Dupixent, I’d estimate we’re looking at $50–$90 per lead for medical-record-verified claimants because the audience is searchable (patients who mention Dupixent + eye problems, or Dupixent + worsening esophagitis are rare enough that targeting is precise, but large enough that volume scales).

Facebook targeting strategy: We layer multiple audiences. First, interest-based: people interested in atopic dermatitis support groups, asthma forums, eosinophilic esophagitis patient communities, and eye health. Second, behavioral: people searching for “Dupixent side effects,” “Dupixent eye problems,” “Dupixent eosinophilia.” Third, lookalike audiences: we build from existing claimant databases and expand to similar demographics. Fourth, custom audience exclusions: we exclude people too recently converted on other tort cases, people with life expectancy concerns unrelated to Dupixent, and people outside statute of limitations windows.

The messaging is straightforward: “Did you develop eye disease or worsening eosinophilic conditions while taking Dupixent? You may qualify for legal compensation. Attorney consultation is free and confidential.” Simple landing pages with optical disease education and claimant intake forms drive qualified leads directly into case management. Video testimonials from early claimants (once cases develop a bit further) will increase conversion rates dramatically.

What We Deliver: Transparent, Scalable Campaign Management

MTAA manages the full campaign lifecycle for Dupixent lawsuit side effects 2026 litigation. We don’t mark up ad spend. Our model is transparent: you pay the actual Facebook ad spend (cost of impressions, clicks, conversions) plus a flat 15% fee on total spend. If we spend $100,000 on ads, your fee is $15,000. If we optimize into $200,000, your fee is $30,000. You see exactly what goes to Meta and what you pay us. No surprises, no hidden costs.

We’ve managed $250 million in ad spend across 600+ plaintiff law firms. We’ve launched 100+ mass tort campaigns. We know how to start small ($5,000–$10,000 monthly), test message and audience combinations, identify the highest-converting segments, and then scale into proven channels. For Dupixent, I’d recommend a 6-week test phase: $15,000–$20,000 across multiple audiences, creative variations, and landing page designs. Measure claimant quality, CPL, and case-file rate. Then scale into the channels and creative that work.

Our team handles everything: account management, creative development (ad copy, landing pages, intake forms), audience research and segmentation, daily campaign optimization, lead quality assurance, and monthly reporting. You see real-time dashboards: impressions, clicks, leads, verified claimants, cost per claimant, and projected ROI. We also handle TCPA compliance and state advertising restrictions—Dupixent claims are medical/legal, so regulatory precision is mandatory. We make sure every ad, every landing page, every intake form complies with state bar rules and FTC guidelines.

One more thing: we actively monitor case development. If the litigation landscape shifts—if an MDL consolidates, if a bellwether trial result comes in, if a major settlement framework emerges—we adjust messaging and targeting in real time. We don’t run static campaigns. We run adaptive ones that respond to the tort’s actual legal status.

Why Timing Matters in 2026

The Dupixent lawsuit side effects 2026 window is open now because of three convergences: first, FDA label updates are recent and ongoing, which means prescribers are just now reading updated warnings and patients are just now connecting their injuries to the drug; second, early case filings are happening in state courts, so precedent is forming and defense strategy is becoming visible; third, media coverage is starting to surface (patient advocacy groups, health news sites), which means patient awareness is rising. Advertising spend right now captures patients in the peak discovery phase—before they’re bombarded with competing firm messages, before CPL rises due to market saturation, before the MDL stabilizes and settlement frameworks flatten claimant values.

We’ve seen this pattern before. In early torts, CPL is $40–$60 per qualified lead and case settlement values are strong because early cases have superior medical records and causation clarity. By the time an MDL is 18 months old, CPL is $100–$200 and settlement values have compressed 30–50% due to volume and case selection bias. Move now, and you capture the high-value inventory.

Your Next Step

If you’re considering a Dupixent lawsuit side effects 2026 advertising campaign, the first conversation is free. You can reach out to MTAA with your target geography, budget range, and case-building timeline. We’ll analyze TortIntel data specific to your region, model out projected claimant flow and CPL, and design a phased campaign that starts lean and scales proven channels. No commitment, no onboarding fee. Just clarity on whether Dupixent is the right bet for your firm in 2026.

The tort is real. The evidence is documented. The claimant pool is massive. The defendants—Sanofi and Regeneron—have both the resources and the liability exposure to justify aggressive case development. Now is the time to advertise, build inventory, and position your firm in the early wave of Dupixent litigation. Contact MTAA to discuss your strategy.